Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

High expression of MLANA in the plasma of patients with head and neck squamous cell carcinoma as a predictor of tumor progression.

Rodrigues-Junior DM, Tan SS, Lim SK, de Souza Viana L, Carvalho AL, Vettore AL, Iyer NG.

Head Neck. 2019 May;41(5):1199-1205. doi: 10.1002/hed.25510. Epub 2019 Feb 25.

PMID:
30803092
2.

MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.

Arantes LM, Laus AC, Melendez ME, de Carvalho AC, Sorroche BP, De Marchi PR, Evangelista AF, Scapulatempo-Neto C, de Souza Viana L, Carvalho AL.

Oncotarget. 2017 Feb 7;8(6):9911-9921. doi: 10.18632/oncotarget.14253.

3.

Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.

Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R; Head and Neck Cancer Disease Site Group.

Curr Oncol. 2010 Jun;17(3):37-48.

4.

Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma.

Cao W, Feng Z, Cui Z, Zhang C, Sun Z, Mao L, Chen W.

Cancer. 2012 Jun 1;118(11):2858-71. doi: 10.1002/cncr.26575. Epub 2011 Oct 11.

5.

Elevated expression of iASPP in head and neck squamous cell carcinoma and its clinical significance.

Liu Z, Zhang X, Huang D, Liu Y, Zhang X, Liu L, Li G, Dai Y, Tan H, Xiao J, Tian Y.

Med Oncol. 2012 Dec;29(5):3381-8. doi: 10.1007/s12032-012-0306-9. Epub 2012 Jul 20.

PMID:
22815155
6.

Persistently elevated soluble MHC class I polypeptide-related sequence A and transforming growth factor-β1 levels are poor prognostic factors in head and neck squamous cell carcinoma after definitive chemoradiotherapy.

Chen JL, Chang CC, Huang YS, Kuo HY, Chen TY, Wang CW, Kuo SH, Lin YL.

PLoS One. 2018 Aug 10;13(8):e0202224. doi: 10.1371/journal.pone.0202224. eCollection 2018.

7.

Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.

Liu S, Ren B, Gao H, Liao S, Zhai YX, Li S, Su XJ, Jin P, Stroncek D, Xu Z, Zeng Q, Li Y.

J Transl Med. 2017 Sep 6;15(1):189. doi: 10.1186/s12967-017-1289-2.

8.

Potentially novel candidate biomarkers for head and neck squamous cell carcinoma identified using an integrated cell line-based discovery strategy.

Sepiashvili L, Hui A, Ignatchenko V, Shi W, Su S, Xu W, Huang SH, O'Sullivan B, Waldron J, Irish JC, Perez-Ordonez B, Liu FF, Kislinger T.

Mol Cell Proteomics. 2012 Nov;11(11):1404-15. doi: 10.1074/mcp.M112.020933. Epub 2012 Aug 23.

9.

Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas.

Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ.

Clin Cancer Res. 2003 Jan;9(1):59-67.

10.

Long non-coding RNA LOC541471: A novel prognostic biomarker for head and neck squamous cell carcinoma.

Wu H, Yu DH, Wu MH, Huang T.

Oncol Lett. 2019 Feb;17(2):2457-2464. doi: 10.3892/ol.2018.9831. Epub 2018 Dec 14.

11.

Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.

Strati A, Koutsodontis G, Papaxoinis G, Angelidis I, Zavridou M, Economopoulou P, Kotsantis I, Avgeris M, Mazel M, Perisanidis C, Sasaki C, Alix-Panabières C, Lianidou E, Psyrri A.

Ann Oncol. 2017 Aug 1;28(8):1923-1933. doi: 10.1093/annonc/mdx206.

PMID:
28838214
12.

PITX3 DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma.

Sailer V, Holmes EE, Gevensleben H, Goltz D, Dröge F, Franzen A, Dietrich J, Kristiansen G, Bootz F, Schröck A, Dietrich D.

Clin Epigenetics. 2017 Feb 2;9:12. doi: 10.1186/s13148-017-0317-7. eCollection 2017.

13.

TRIM24 overexpression is common in locally advanced head and neck squamous cell carcinoma and correlates with aggressive malignant phenotypes.

Cui Z, Cao W, Li J, Song X, Mao L, Chen W.

PLoS One. 2013 May 22;8(5):e63887. doi: 10.1371/journal.pone.0063887. Print 2013.

14.

nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma.

Adkins D, Ley J, Michel L, Wildes TM, Thorstad W, Gay HA, Daly M, Rich J, Paniello R, Uppaluri R, Jackson R, Trinkaus K, Nussenbaum B.

Oral Oncol. 2016 Oct;61:1-7. doi: 10.1016/j.oraloncology.2016.07.015. Epub 2016 Jul 29.

15.

Nuclear NF-κB expression correlates with outcome among patients with head and neck squamous cell carcinoma treated with primary chemoradiation therapy.

Balermpas P, Michel Y, Wagenblast J, Seitz O, Sipek F, Rödel F, Rödel C, Fokas E.

Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):785-90. doi: 10.1016/j.ijrobp.2013.04.001. Epub 2013 May 9.

PMID:
23664323
16.

Prognostic value of PET/CT with (18)F-fluoroazomycin arabinoside for patients with head and neck squamous cell carcinomas receiving chemoradiotherapy.

Saga T, Inubushi M, Koizumi M, Yoshikawa K, Zhang MR, Obata T, Tanimoto K, Harada R, Uno T, Fujibayashi Y.

Ann Nucl Med. 2016 Apr;30(3):217-24. doi: 10.1007/s12149-015-1048-5. Epub 2015 Dec 12.

PMID:
26662072
17.

Loss of SOX2 expression induces cell motility via vimentin up-regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma.

Bayo P, Jou A, Stenzinger A, Shao C, Gross M, Jensen A, Grabe N, Mende CH, Rados PV, Debus J, Weichert W, Plinkert PK, Lichter P, Freier K, Hess J.

Mol Oncol. 2015 Oct;9(8):1704-19. doi: 10.1016/j.molonc.2015.05.006. Epub 2015 May 20.

18.

PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions.

Szczepanski MJ, DeLeo AB, Łuczak M, Molinska-Glura M, Misiak J, Szarzynska B, Dworacki G, Zagor M, Rozwadowska N, Kurpisz M, Krzeski A, Kruk-Zagajewska A, Kopec T, Banaszewski J, Whiteside TL.

Oral Oncol. 2013 Feb;49(2):144-51. doi: 10.1016/j.oraloncology.2012.08.005. Epub 2012 Sep 1.

19.

Prognostic value of circulating tumor cells with podoplanin expression in patients with locally advanced or metastatic head and neck squamous cell carcinoma.

Hsieh JC, Lin HC, Huang CY, Hsu HL, Wu TM, Lee CL, Chen MC, Wang HM, Tseng CP.

Head Neck. 2015 Oct;37(10):1448-55. doi: 10.1002/hed.23779. Epub 2014 Jul 24.

PMID:
24844673
20.

The Stem Cell Factor HMGA2 Is Expressed in Non-HPV-Associated Head and Neck Squamous Cell Carcinoma and Predicts Patient Survival of Distinct Subsites.

Günther K, Foraita R, Friemel J, Günther F, Bullerdiek J, Nimzyk R, Markowski DN, Behrens T, Ahrens W.

Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):197-205. doi: 10.1158/1055-9965.EPI-16-0492. Epub 2016 Oct 14.

Supplemental Content

Support Center